The transaction transfers effective control of ZEO to Pluri with massive dilution to existing shareholders. Monitor closing conditions, particularly IIA approval and the independent valuations. If the deal closes, watch for the remediation plan timeline and any subsequent Nasdaq uplist efforts, as well as the exercise of warrants and milestone triggers.
Price Chart
Executive Summary
Zeo ScientifiX entered into a definitive partnership agreement with Pluri Inc., under which Pluri will grant ZEO an exclusive license to manufacture and commercialize Pluri's regenerative medicine product portfolio in the U.S. in exchange for 50% of ZEO's outstanding common stock, board control, and milestone-based warrants. The transaction involves massive dilution to existing ZEO shareholders (Pluri receives 41% at closing, rising to 50% via secondary sales) and grants Pluri effective voting control through Series D Preferred Shares representing 51% of total voting power. Closing is subject to multiple conditions including IIA approval and is expected in Q4 2026.
Key Financial Metrics
Key Facts
- Pluri receives 41% of ZEO common stock at closing, rising to 50% after secondary sales
- Series D Preferred Shares give Pluri and consenting shareholders 51% of total voting power
- Pluri gets right to designate 4 of 7 board seats
- Two warrants issued: one for 5% of ZEO shares at $4.00, one for 2.5% at $5.50, both 5-year terms
- Tranche B milestone: additional 5% of ZEO shares if 10-day VWAP reaches $5.50
- Anti-dilution protection for Pluri if existing convertibles under $4.00 are exercised
- Royalty on net sales starts at [***]% while Pluri holds 50%+, increasing to max 7% as ownership declines
- Closing subject to IIA approval, due diligence, valuations, and other conditions; 90-day outside date
- ZEO must remediate internal control weaknesses described in its FY2025 10-K within 6 months of closing
- License is exclusive, non-sublicensable, and limited to U.S. regenerative medicine field
Financial Impact
Massive dilution: Pluri receives 41% of ZEO common stock at closing, rising to 50% via secondary sales, plus warrants for additional 7.5% and milestone shares for another 5%. Series D Preferred Shares control 51% of voting power. No cash consideration stated.
Risk Factors
- Closing is not guaranteed; subject to IIA approval, due diligence, valuations, and other conditions
- Existing ZEO shareholders face extreme dilution with Pluri obtaining 50% ownership
- Series D Preferred Shares concentrate 51% voting power in Pluri and consenting shareholders, marginalizing public shareholders
- ZEO must fund all manufacturing and commercialization costs with no stated capital commitment from Pluri
- ZEO has identified material weaknesses in internal controls that require remediation
- License is non-sublicensable and non-transferable, limiting ZEO's strategic flexibility
- document contains text addressed to automated readers
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001829126-26-011800 |
| Document: zeoscientifix_8k.htm | 0001829126-26-011800 |
| Document: 0001829126-26-011800-index-headers.html | 0001829126-26-011800 |
| Document: 0001829126-26-011800-index.html | 0001829126-26-011800 |
| Document: 0001829126-26-011800.txt | 0001829126-26-011800 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 30, 2026 2d ago | 8-K | $1.27 | awaiting T+20 | awaiting T+20 | $1.36 (−7.09%) |
Oct 26, 2026 6d ago | 8-K | $1.50 | awaiting T+20 | awaiting T+20 | $1.36 (−9.33%) |
Sep 15, 2026 6w ago | 8-K | $1.36 $1.15 | ▼ −15.44% | ▼ −18.42% | $1.36 (+0.00%) |
Sep 1, 2026 8w ago | 8-K | $1.20 $1.39 | ▲ +15.83% | ▲ +14.65% | $1.36 (+13.33%) |
Aug 4, 2026 12w ago | 8-K | $1.40 $1.20 | ▼ −14.16% | ▼ −12.93% | $1.36 (−2.72%) |
Jul 21, 2026 14w ago | 8-K | $1.69 $1.55 | ▼ −8.28% | ▼ −10.85% | $1.36 (−19.53%) |
Jul 8, 2026 16w ago | 8-K | $1.80 $1.40 | ▼ −22.33% | ▼ −25.61% | $1.36 (−24.44%) |
Jul 1, 2026 17w ago | 8-K | $1.77 $1.65 | ▼ −6.78% | ▼ −4.59% | $1.36 (−23.16%) |
Jun 16, 2026 19w ago | 8-K | $1.72 $1.94 | ▲ +12.79% | ▲ +11.93% | $1.36 (−20.93%) |
Jun 9, 2026 20w ago | 8-K | $1.67 $1.80 | ▲ +7.78% | ▲ +6.39% | $1.36 (−18.56%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers